Welcome to our dedicated page for BIOGEN SEC filings (Ticker: BIIB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biogen Inc. filings document the regulatory record of a Nasdaq-listed biopharmaceutical company with commercial products and development programs in neurology, rare disease and immune-mediated conditions. Forms 8-K cover operating and financial results, product-revenue commentary, acquired in-process research and development, upfront and milestone expenses, collaboration and license-agreement costs, material agreements, capital-structure disclosures and clinical or regulatory updates.
Biogen’s proxy and governance filings address board leadership, director matters, executive compensation and annual meeting items. The filing record also documents the company’s common stock registered on The Nasdaq Global Select Market, officer and director transitions, risk-related forward-looking disclosures and transaction communications tied to strategic business development activity.
Biogen Inc. — The Vanguard Group filed Amendment No. 13 to a Schedule 13G/A reporting zero shares of Biogen common stock and 0% beneficial ownership following an internal realignment.
The filing states certain Vanguard subsidiaries will report holdings separately under SEC Release No. 34-39538, effective after the January 12, 2026 realignment. The report is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
Biogen Inc. reported that its Chief Legal Officer, Susan H. Alexander, will leave the company effective at the end of May 2026. The company has started a search for her successor to lead its legal function. Other aspects of Biogen’s operations are not discussed in this report.
Viehbacher Christopher reported acquisition or exercise transactions in this Form 4 filing.
BIOGEN INC. reported that President and CEO Christopher Viehbacher received a grant of 38,015 restricted stock units on February 13, 2026. These units are a form of equity compensation and were awarded at a stated price of $0.00 per unit.
The restricted stock units vest in three equal yearly installments, beginning on the first anniversary of the grant date of February 13, 2026. This means the award is structured to vest over three years, aligning the CEO’s compensation with longer-term company performance.
Singhal Priya reported acquisition or exercise transactions in this Form 4 filing.
BIOGEN INC. reported that Priya Singhal, Head of Development, received a grant of 10,560 restricted stock units. These RSUs were awarded at no cash cost per unit as part of equity compensation. According to the disclosure, the units vest in three equal yearly installments beginning on the first anniversary of the February 13, 2026 grant date.
BIOGEN INC. executive Nicole Murphy reported a grant of 10,560 restricted stock units and a small open-market share purchase. The restricted stock units were awarded on February 13, 2026 and vest in three equal yearly installments starting on the first anniversary of that grant date. On February 12, 2026 she bought 3 shares of Biogen common stock in an open-market transaction at a price of $195.035 per share. Following these transactions, her direct holdings total 19,611.0408 shares of common stock and 10,560 restricted stock units.
Biogen Inc. reported that Chief Financial Officer Robin Kramer acquired 8,450 restricted stock units as a grant on February 13, 2026. The RSUs were awarded at a price of $0.00 per unit, reflecting equity-based compensation rather than an open-market purchase.
According to the footnote, these restricted stock units vest in three equal yearly installments, beginning on the first anniversary of the grant date of February 13, 2026. After this grant, Kramer directly holds 8,450 RSUs, which may convert into Biogen shares as they vest.
Keeney Adam reported acquisition or exercise transactions in this Form 4 filing.
Biogen Inc. executive Adam Keeney, Head of Corporate Development, reported an award of 8,025 restricted stock units. These RSUs were granted at no purchase price and represent the right to receive Biogen common shares upon vesting. The units vest in three equal yearly installments beginning on the first anniversary of the February 13, 2026 grant date.
Izzar Rachid reported acquisition or exercise transactions in this Form 4 filing.
BIOGEN INC. executive Rachid Izzar, Head of Global Product Strategy, received a grant of 7,390 restricted stock units. These RSUs were awarded at no cash cost per unit and represent a form of stock-based compensation that aligns the executive’s interests with shareholders.
The restricted stock units vest in three equal yearly installments, beginning on the first anniversary of the February 13, 2026 grant date. The entire 7,390-unit award is reported as directly owned following the transaction.
Grogan Jane reported acquisition or exercise transactions in this Form 4 filing.
BIOGEN INC. reported that Head of Research Jane Grogan received a grant of 8,450 restricted stock units (RSUs) on February 13, 2026. These RSUs vest in three equal yearly installments, beginning on the first anniversary of the grant date, providing her with long-term, equity-based compensation rather than an open-market share purchase or sale.
Gregory Ginger reported acquisition or exercise transactions in this Form 4 filing.
BIOGEN INC. executive Gregory Ginger, EVP of Human Resources, received an equity grant of 8,025 restricted stock units on February 13, 2026. These RSUs were awarded at no cash cost to him as part of his compensation and represent a right to receive Biogen shares in the future.
The 8,025 restricted stock units vest in three equal yearly installments, beginning on the first anniversary of the February 13, 2026 grant date. All units are reported as directly owned following the grant, meaning his reported derivative holdings increased by the full award amount.